Emese Zsiros, MD, PhD, FACOG, assistant professor of oncology, Department of Gynecologic Oncology, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center explains the rationale for the a phase II study, which combined pembrolizumab with bevacizumab in patients with recurrent ovarian cancer. Zsiros presented data on the study in early 2019 at the SGO Annual Meeting.
Emese Zsiros, MD, PhD, FACOG, assistant professor of oncology, Department of Gynecologic Oncology, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, explains the rationale for the a phase II study, which combined pembrolizumab (Keytruda) with bevacizumab (Avastin) in patients with recurrent ovarian cancer. Zsiros presented data on the study in early 2019 at the Society of Gynecologic Oncology (SGO) Annual Meeting.
The rationale for the phase II open-label study of pembrolizumab plus bevacizumab versus pembrolizumab alone was to understand whether the efficacy seen with single-agent pembrolizumab can be enhanced with the addition of bevacizumab, an anti-angiogenic agent and an oral cyclophosphamide.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More